Hormonal
GLP-1 receptor agonists (specifically semaglutide 2.4 mg and tirzepatide) produce significant weight loss (14.9-20.9%) and improve cardiometabolic risk factors in adults with overweight or obesity, regardless of diabetes status.
If you have overweight or obesity, GLP-1 agonists like semaglutide or tirzepatide are highly effective for weight loss, producing 15-21% body weight reduction in clinical trials. These benefits occur even if you do not have diabetes. Discuss these options with your provider, keeping in mind that cost and access may be barriers, but coverage is expanding for cardiovascular risk reduction.
In STEP 1, participants without diabetes achieved a mean weight reduction of 14.9% at 68 weeks compared to 2.4% with placebo (p < 0.001)... At the lowest dose (5 mg weekly), participants lost an average of 15% of their body weight over 72 weeks, while participants who received the highest dose (15 mg weekly) lost an average of 20.9% of their body weight over 72 weeks compared to 3.1% with placebo
Why this rating
Based on large-scale, randomized, placebo-controlled trials (STEP 1, SURMOUNT-1) with statistically significant results.
Source
Beyond Diabetes: A Review of Emerging Indications for Glucagon-Like Peptide-1 Receptor Agonists
Lucianne West et al. · Reviews in Cardiovascular Medicine · 2026
DOI 10.31083/rcm44528
More from this paper
- GLP-1 receptor agonists improve cardiovascular outcomes in patients with atherosclerotic cardiovascular disease (ASCVD) and heart failure with preserved ejection fraction (HFpEF), but may increase heart failure hospitalization risk in patients with heart failure with reduced ejection fraction (HFrEF).Strong
- GLP-1 receptor agonists provide renal benefits, including reduced albuminuria and slower eGFR decline, in patients with type 2 diabetes and chronic kidney disease, independent of glycemic control.Good
- GLP-1 receptor agonists (semaglutide, tirzepatide, survodutide, retatrutide) promote resolution of metabolic dysfunction-associated steatohepatitis (MASH) and improve liver fibrosis in patients with MASLD/MASH.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →